[go: up one dir, main page]

WO2019011337A1 - Qaw-039的晶型及其制备方法和用途 - Google Patents

Qaw-039的晶型及其制备方法和用途 Download PDF

Info

Publication number
WO2019011337A1
WO2019011337A1 PCT/CN2018/095694 CN2018095694W WO2019011337A1 WO 2019011337 A1 WO2019011337 A1 WO 2019011337A1 CN 2018095694 W CN2018095694 W CN 2018095694W WO 2019011337 A1 WO2019011337 A1 WO 2019011337A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline form
preparation
crystal form
compound
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2018/095694
Other languages
English (en)
French (fr)
Inventor
陈敏华
张炎锋
王金秋
钱佳乐
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmaceutical Suzhou Co Ltd
Original Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmaceutical Suzhou Co Ltd filed Critical Crystal Pharmaceutical Suzhou Co Ltd
Publication of WO2019011337A1 publication Critical patent/WO2019011337A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the invention relates to the field of pharmaceutical crystal technology. Specifically, it relates to a crystal form of QAW-039 and a preparation method and use thereof.
  • QAW-039 (Fevipiprant) is a potential prostaglandin D2 receptor 2 (DP2/CRTh2) antagonist for the treatment of asthma, atopic dermatitis and allergic rhinitis, developed by Novartis.
  • DP2/CRTh2 prostaglandin D2 receptor 2
  • QAW-039 has achieved positive results in clinical trials, reducing eosinophils that play a role in airway inflammation, safely and effectively reducing eosinophilic airway inflammation in patients with moderate or severe asthma, and improving patients.
  • the lung function and quality of life are expected to be innovative asthma drugs in recent decades.
  • the present inventors have found crystalline forms CS5 and CS6 of the compound (I) excellent in properties.
  • the crystal form of the present invention is at least one of stability, melting point, solubility, in vitro and in vivo dissolution, wettability, bioavailability, adhesion, compressibility, fluidity, and processability, purification, formulation production, and the like. There are advantages, especially low wetting, good stability, high dissolution, and strong developability of the preparation, which provides a new and better choice for the development of drugs containing QAW-039, which is of great significance.
  • the main object of the present invention is to provide a novel crystalline form of the compound (I), a process for its preparation and use.
  • the present invention also provides the crystal form CS5 of the compound (I) (hereinafter referred to as "crystal form CS5").
  • the X-ray powder diffraction of the crystal form CS5 has a characteristic peak at a diffraction angle 2 ⁇ value of 13.6 ° ⁇ 0.2 °, 19.6 ° ⁇ 0.2 °, 21.5 ° ⁇ 0.2 °.
  • the X-ray powder diffraction of the crystalline form CS5 has characteristics at one, or two, or three of the diffraction angle 2 ⁇ values of 4.7° ⁇ 0.2°, 20.2° ⁇ 0.2°, and 22.7° ⁇ 0.2°. peak.
  • the X-ray powder diffraction of the crystalline form CS5 has characteristic peaks at diffraction angle 2 ⁇ values of 4.7° ⁇ 0.2°, 20.2° ⁇ 0.2°, and 22.7° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystal form CS5 has one, or two, or three places in the diffraction angle 2 ⁇ value of 8.4° ⁇ 0.2°, 10.6° ⁇ 0.2°, and 24.6° ⁇ 0.2°. Characteristic peaks.
  • the X-ray powder diffraction of the crystalline form CS5 has characteristic peaks at diffraction angle 2 ⁇ values of 8.4° ⁇ 0.2°, 10.6° ⁇ 0.2°, and 24.6° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS5 has a diffraction angle 2 ⁇ of 13.6° ⁇ 0.2°, 19.6° ⁇ 0.2°, 21.5° ⁇ 0.2°, 4.7° ⁇ 0.2°, and 20.2° ⁇ 0.2°. Any of 22.7° ⁇ 0.2°, 8.4° ⁇ 0.2°, 10.6° ⁇ 0.2°, 24.6° ⁇ 0.2°, 16.1° ⁇ 0.2°, 23.5° ⁇ 0.2°, 26.2° ⁇ 0.2°, 27.5° ⁇ 0.2° There are three, or four, or five, or six, or seven, or eight, or nine, or ten, or eleven, or twelve, or 13 characteristic peaks.
  • the X-ray powder diffraction pattern of Form CS5 is as shown in FIG.
  • the present invention further provides a method for preparing a crystalline form CS5, which comprises: dissolving a raw material of the compound (I) in an alcohol solvent system, stirring and crystallization, separating and drying to obtain .
  • the alcohol solvent is preferably methanol, or ethanol, or propanol, or any mixture thereof, and the crystallization time is preferably from 1 to 15 days;
  • the alcohol solvent is preferably a mixed solvent of methanol and ethanol, and the crystallization time is preferably 5 days;
  • volume ratio of methanol to ethanol is preferably from 1:3 to 3:1, more preferably from 1:1.
  • the crystal form CS5 provided by the invention has the following beneficial effects:
  • the crystalline form CS5 provided by the invention has high solubility in simulated biological medium and pure water, and provides a good solution for the good dissolution of the crystalline form in the preparation, and is beneficial to the effective absorption of the active ingredient in the preparation in the preparation, and achieves an ideal Drug bioavailability and efficacy.
  • the crystalline form CS5 of the present invention has a uniform particle size distribution. Its uniform particle size helps to simplify the post-treatment process of the formulation process, such as reducing the grinding of the crystal, saving cost, reducing the crystallinity change and the risk of crystal transformation in the grinding, and improving the quality control.
  • the present invention also provides the crystal form CS6 of the compound (I) (hereinafter referred to as "crystal form CS6").
  • the X-ray powder diffraction of the crystal form CS6 has a characteristic peak at a diffraction angle 2 ⁇ value of 10.1 ⁇ 0.2°, 15.5° ⁇ 0.2°, and 20.1° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS6 has characteristics at one, or two, or three of the diffraction angle 2 ⁇ values of 12.2° ⁇ 0.2°, 27.3° ⁇ 0.2°, and 30.3° ⁇ 0.2°. peak.
  • the X-ray powder diffraction of the crystalline form CS6 has characteristic peaks at diffraction angle 2 ⁇ values of 12.2 ° ⁇ 0.2 °, 27.3 ° ⁇ 0.2 °, and 30.3 ° ⁇ 0.2 °.
  • the X-ray powder diffraction of the crystalline form CS6 has a diffraction angle 2 ⁇ value of 10.1 ⁇ 0.2°, 15.5° ⁇ 0.2°, 20.1° ⁇ 0.2°, 12.2° ⁇ 0.2°, 27.3° ⁇ 0.2°, There are characteristic peaks at any 3, or 4, or 5, or 6 of 30.3 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form CS6 is as shown in FIG.
  • the present invention also provides a method for preparing a crystal form CS6, which comprises: dissolving a compound (I) as a raw material in a mixed system of a ketone and an alcohol solvent, and adding a high polymer. After evaporation, it is obtained.
  • the ketone solvent is preferably acetone, or methyl ethyl ketone, or a mixture thereof, and the alcohol solvent is preferably methanol, or ethanol, or isopropanol, or any mixture thereof, the ketone
  • the volume ratio of the solvent-like solvent to the alcohol solvent (v:v) is preferably from 1:15 to 15:1, the crystallization time is preferably from 1 to 15 days, and the high polymer is composed of equal-mass polycaprolactone, Polyoxyethylene, polymethyl methacrylate, hydroxyethyl cellulose and sodium alginate;
  • the ketone solvent is preferably acetone
  • the alcohol solvent is preferably ethanol
  • the volume ratio (v:v) of the ketone solvent to the alcohol solvent is preferably 1:3, and the crystallization time is It is preferably 5 days.
  • the crystal form CS6 provided by the invention has the following beneficial effects:
  • the crystal form CS6 provided by the present invention has good stability.
  • the crystalline bulk drug provided by the invention has good physical and chemical stability.
  • the crystalline form CS6 did not change at 25 ° C / 60% relative humidity for at least 3 months, its chemical purity was above 99%, and the chemical purity remained basically unchanged during the placement process.
  • the crystalline form provided by the present invention has good physical and chemical stability in the formulation.
  • the crystalline form CS6 of the present invention is mixed with an adjuvant to form a pharmaceutical preparation, and is allowed to stand at 25 ° C / 60% relative humidity and 40 ° C / 75% relative humidity for at least 3 months, and the crystal form of the present invention remains unchanged in the preparation.
  • the crystalline bulk drug and preparation have good physical and chemical stability. During the storage and formulation process, the crystalline form CS6 will not be converted into other crystal forms, and the chemical purity of the crystalline form CS6 remains basically unchanged during storage. In order to ensure the quality of the drug substance and preparation is consistent and controllable.
  • the crystalline form CS6 provided by the present invention has low wettability, and after weight equilibration at 80% relative humidity, the weight gain is about 1.17%, which is slightly wettability.
  • Humidity affects the stability of the drug, fluidity and uniformity during processing, and ultimately affects the quality of the drug formulation. Humidity also affects the preparation, storage and post-treatment of the drug.
  • the low moisture absorbing crystal form has strict requirements on storage conditions, reduces material storage and quality control costs, and has strong economic value.
  • the crystalline form CS6 provided by the invention has good solubility in simulated biological medium and pure water, and provides a good solution for the good dissolution of the crystalline form in the preparation, and is beneficial to the effective absorption of the active ingredient in the preparation in the human body, and achieves an ideal medicine. Bioavailability and efficacy.
  • the crystalline form CS6 of the present invention also has good dissolution and dissolution rates.
  • Dissolution is a prerequisite for absorption.
  • Good in vitro dissolution makes the absorption of the drug higher, and the in vivo exposure characteristics are better, thereby improving the bioavailability and improving the efficacy of the drug; a good in vitro dissolution rate allows the drug to be administered after the drug is administered. The highest concentration can be reached quickly in the plasma, thus ensuring rapid drug action.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form CS5, CS6 of the present invention or any mixture thereof, and at least one pharmaceutically acceptable carrier , diluent or excipient.
  • crystalline form CS5, CS6 or any combination thereof provided by the present invention for the preparation of a pharmaceutical preparation of a prostaglandin D2 receptor 2 antagonist.
  • the present invention provides the use of the crystalline forms CS5 and CS6 or any combination thereof in the preparation of a pharmaceutical preparation for the treatment of asthma and/or atopic dermatitis and/or allergic rhinitis.
  • the compound (I) as a raw material means a solid (crystalline or amorphous), semi-solid, wax or oil form.
  • the compound of formula (I) as a starting material is in the form of a solid powder.
  • crystal or “polymorph” means confirmed by the X-ray diffraction pattern characterization shown.
  • X-ray diffraction pattern will generally vary with the conditions of the instrument. It is particularly important to note that the relative intensities of the X-ray diffraction patterns may also vary with experimental conditions, so the order of peak intensities cannot be the sole or decisive factor. In fact, the relative intensity of the diffraction peaks in the XRPD pattern is related to the preferred orientation of the crystal.
  • the peak intensities shown here are illustrative and not for absolute comparison.
  • the experimental error of the peak angle is usually 5% or less, and the error of these angles should also be taken into account, and an error of ⁇ 0.2° is usually allowed.
  • the overall offset of the peak angle is caused, and a certain offset is usually allowed.
  • the X-ray diffraction pattern of one crystal form in the present invention is not necessarily identical to the X-ray diffraction pattern in the example referred to herein, and the "XRPD pattern is the same" as used herein does not mean absolutely the same.
  • the same peak position can differ by ⁇ 0.2° and the peak intensity allows for some variability.
  • Any crystal form having a map identical or similar to the characteristic peaks in these maps is within the scope of the present invention.
  • One skilled in the art will be able to compare the maps listed herein with a map of an unknown crystal form to verify whether the two sets of maps reflect the same or different crystal forms.
  • the crystalline forms CS5 and CS6 of the present invention are pure, unitary, and are substantially free of any other crystalline form.
  • substantially free when used to refer to a new crystalline form means that the crystalline form contains less than 20% by weight of other crystalline forms, especially less than 10% by weight of other crystalline forms, more Other crystal forms of 5% by weight, more preferably less than 1% by weight of other crystal forms.
  • Figure 1 is an XRPD pattern of a crystal form CS5 obtained according to Example 1 of the present invention.
  • Example 2 is a DSC chart of a crystal form CS5 obtained according to Example 1 of the present invention.
  • Figure 3 is a TGA diagram of a crystalline form CS5 obtained in accordance with Example 1 of the present invention.
  • Example 4 is an XRPD pattern of a crystal form CS5 obtained according to Example 2 of the present invention.
  • Figure 5 is a PSD diagram of a crystalline form CS5 of the present invention.
  • Figure 6 is an XRPD pattern of a crystalline form CS6 obtained according to Example 3 of the present invention.
  • Figure 7 is a 1 H NMR chart of the crystalline form CS6 obtained according to Example 3 of the present invention.
  • Figure 8 is a DSC chart of a crystalline form CS6 obtained according to Example 3 of the present invention.
  • Figure 9 is a TGA diagram of a crystalline form CS6 obtained in accordance with Example 3 of the present invention.
  • Figure 10 is a DVS diagram of the crystalline form CS6 of the present invention.
  • Figure 11 is an XRPD pattern of the crystalline form CS6 of the present invention placed at 25 ° C / 60% relative humidity for 6 months (the top view is before placement and the lower figure is after placement).
  • Figure 12 is an in vitro dissolution profile of a crystalline form CS6 tablet of the present invention.
  • the invention is further defined by the following examples which describe in detail the preparation and use of the crystalline forms of the invention.
  • PSD particle size distribution
  • the X-ray powder diffraction pattern of the present invention was collected on a Panalytical Empyrean X-ray powder diffractometer.
  • the method parameters of the X-ray powder diffraction described in the present invention are as follows:
  • Scan range: from 3.0 to 40.0 degrees
  • the differential scanning calorimetry (DSC) map of the present invention was acquired on a TA Q2000.
  • the method parameters of the differential scanning calorimetry (DSC) described in the present invention are as follows:
  • thermogravimetric analysis (TGA) map of the present invention was taken on a TA Q500.
  • the method parameters of the thermogravimetric analysis (TGA) described in the present invention are as follows:
  • the dynamic moisture adsorption (DVS) pattern of the present invention was collected on an Intrinsic dynamic moisture adsorber manufactured by SMS Corporation (Surface Measurement Systems Ltd.).
  • the method parameters of the dynamic moisture adsorber are as follows:
  • Relative humidity range 0%RH-95%RH
  • HPLC high performance liquid chromatography
  • HPLC high performance liquid chromatography
  • the particle size distribution results described in the present invention were collected on a Microtrac S3500 laser particle size analyzer.
  • the Microtrac S3500 is equipped with an SDC (Sample Delivery Controller) injection system. This test uses a wet method and the dispersion medium is Isopar G.
  • the method parameters of the laser particle size analyzer are as follows:
  • the flow rate is 60% of 60% of 65 ml/sec.
  • H NMR data (1 HNMR) collected from a Bruker Avance II DMX 400M HZ NMR spectrometer. A sample of 1-5 mg was weighed and dissolved in 0.5 mL of deuterated dimethyl sulfoxide to prepare a solution of 2-10 mg/mL.
  • room temperature is not an accurate temperature value and refers to a temperature range of 10-30 °C.
  • the QAW-039 used in the following examples was prepared according to the prior art, for example according to the preparation method disclosed in WO2005123731A1.
  • the DSC of the crystalline form CS5 obtained in this example showed an endothermic peak near the temperature of 95 ° C, and the endothermic peak was the dehydration endothermic peak of the crystalline form CS5.
  • the TGA of the form CS5 obtained in this example is as shown in Fig. 3, and has a weight loss of about 10.2% when heated to around 140 °C.
  • Gastrointestinal fluids such as SGF (simulated gastric fluid), FaSSIF (simulated fasting intestinal fluid), FeSSIF (simulated feeding intestinal fluid) are biologically relevant media, and such media can better reflect the gastrointestinal physiological environment for drug release.
  • SGF simulated gastric fluid
  • FaSSIF simulated fasting intestinal fluid
  • FeSSIF simulated feeding intestinal fluid
  • the crystalline form CS5 of the present invention was dissolved in a saturated solution of SGF, FaSSIF, FeSSIF and water, respectively, and after 1 hour of equilibrium, the content of the sample in the saturated solution (microgram/ml) was measured by high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • D10 indicates the particle size distribution (volume distribution) accounts for 10% of the particle size
  • D50 indicates the particle diameter corresponding to the particle size distribution (volume distribution), which is also called the median diameter.
  • D90 indicates the particle size distribution (volume distribution) accounts for 90% of the particle size
  • the nuclear magnetic resonance spectrum is shown in Fig. 7.
  • the DSC of the crystalline form CS6 obtained in this example showed an endothermic peak near the temperature of 46 ° C, and the endothermic peak was the dehydration endothermic peak of the crystalline form CS6.
  • the TGA of the crystalline form CS6 obtained in this example is as shown in Fig. 9, and has a weight loss of about 5.5% when heated to around 140 °C.
  • the wetting weight gain is not less than 15.0%
  • Humidity Wet weight gain is less than 15.0% but not less than 2.0%
  • wet weight gain is less than 2.0% but not less than 0.2%
  • wetting gain is less than 0.2%
  • the crystalline form CS6 of the present invention has no change in crystal form and the chemical purity remains substantially unchanged after being left for 3 months under the condition of 25 ° C / 60% relative humidity, indicating that the crystalline form CS2 of the present invention has good physical and chemical stability.
  • Example 8 Dynamic solubility of crystalline form CS6
  • Gastrointestinal fluids such as SGF (simulated gastric fluid), FaSSIF (simulated fasting intestinal fluid), FeSSIF (simulated feeding intestinal fluid) are biologically relevant media, and such media can better reflect the gastrointestinal physiological environment for drug release.
  • SGF simulated gastric fluid
  • FaSSIF simulated fasting intestinal fluid
  • FeSSIF simulated feeding intestinal fluid
  • the crystalline form CS6 of the present invention was dissolved in a saturated solution of SGF, FaSSIF, FeSSIF and water, respectively, and after 1 hour of equilibrium, the content of the sample in the saturated solution (microgram/ml) was measured by high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • the crystalline form CS6 of the invention has good solubility in SGF, FeSSIF, FaSSIF and pure water, which provides a good solution for the good dissolution of the crystal form in the preparation, and is beneficial to the effective absorption of the active ingredient in the preparation in the preparation, which is ideal. Drug bioavailability and efficacy.
  • the crystalline form CS6, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate (the contents of the respective components shown in Table 9 below) of the compound (I) were weighed and mixed for 2 minutes. It was pressed into a piece by a manual tableting machine, and a circular die of 6 mm in diameter was pressed at a pressure of 5 KN ⁇ 1 KN, and the tablet weight was 75 mg ⁇ 1 mg. Packed in 35cc HDPE bottles (one per bottle), each bottle contains 1g desiccant and sealed with a sealing machine. The crystal form of the active ingredient was not changed before and after preparation of the preparation.
  • the tablets prepared above were allowed to stand under conditions of 25 ° C / 60% relative humidity and 40 ° C / 75% relative humidity for 3 months, and the crystal form did not change in the tablets containing the crystalline form CS6.
  • the results are shown in Table 10 below, indicating that the crystalline form CS6 has good stability in the formulation.
  • Example 10 In vitro dissolution and in vitro dissolution rate of crystalline CS6
  • the tablets containing the crystalline form CS6 obtained in Example 9 were tested for dissolution in vitro, and the dissolution was measured according to the Chinese Pharmacopoeia 2015 edition 0931 dissolution and release assay conditions, as follows:
  • Dissolution method paddle method
  • the in vitro dissolution of the crystalline form CS6 is shown in Table 11 below, and it is shown in Fig. 12 that the tablet having the crystalline form of the present invention as an active ingredient has a good dissolution rate and a dissolution rate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

涉及化合物(I)的晶型及其制备方法和用途，含有该晶型的药物组合物，以及该晶型在制备前列腺素D2受体2拮抗剂和治疗哮喘或过敏性皮炎或过敏性鼻炎药物制剂中的用途。所述晶型引湿性低、稳定性好、溶出度高、制剂可开发性强，为含化合物(I)的药物开发提供了新的更好的选择。

Description

QAW-039的晶型及其制备方法和用途 技术领域
本发明涉及药物晶体技术领域。具体而言，涉及QAW-039的晶型及其制备方法和用途。
背景技术
QAW-039(Fevipiprant)是一种潜在的治疗哮喘、过敏性皮炎和过敏性鼻炎的前列腺素D2受体2(DP2/CRTh2)拮抗剂，由诺华研发。QAW-039在临床试验中取得了积极的效果，减少在气道炎症中起作用的嗜酸性粒细胞，可以安全有效地降低中度或重度哮喘患者的嗜酸性粒细胞气道炎症反应，改善患者的肺功能和生活质量，有望成为近几十年来的创新型哮喘药物。
QAW-039的化学名称为：[1-(4-((甲烷)磺酰基)-2-三氟甲基苯甲基)-2-甲基-1H-吡咯并[2,3-b]吡啶-3-基]乙酸(以下称为“化合物(I)”)，其结构式如下：
Figure PCTCN2018095694-appb-000001
目前无化合物(I)的晶型信息公开，因此，需要开发化合物(I)的晶型，寻找适合药用的优势晶型，以适于药物的工业化生产要求。本发明人发现了性质优良的化合物(I)的晶型CS5和CS6。本发明的晶型在稳定性、熔点、溶解度、体内外溶出、引湿性、生物有效性、黏附性、可压性、流动性以及加工性能、提纯作用、制剂生产等方面中的至少一方面上存在优势，特别是引湿性低、稳定性好、溶出度高、制剂可开发性强，为含QAW-039的药物开发提供了新的更好的选择，具有非常重要的意义。
发明内容
本发明的主要目的是提供化合物(I)的新晶型及其制备方法和用途。
根据本发明的目的，本发明还提化合物(I)的晶型CS5(以下称作“晶型CS5”)。
一方面，使用Cu-Kα辐射，所述晶型CS5的X射线粉末衍射在衍射角2θ值为13.6°±0.2°、 19.6°±0.2°、21.5°±0.2°处有特征峰。
进一步地，所述晶型CS5的X射线粉末衍射在衍射角2θ值为4.7°±0.2°、20.2°±0.2°、22.7°±0.2°中的1处、或2处、或3处有特征峰。优选的，所述晶型CS5的X射线粉末衍射在衍射角2θ值为4.7°±0.2°、20.2°±0.2°、22.7°±0.2°处均有特征峰。
更进一步地，所述晶型CS5的X射线粉末衍射在衍射角2θ值为8.4°±0.2°、10.6°±0.2°、24.6°±0.2°中的1处、或2处、或3处有特征峰。优选的，所述晶型CS5的X射线粉末衍射在衍射角2θ值为8.4°±0.2°、10.6°±0.2°、24.6°±0.2°处均有特征峰。
另一方面，所述晶型CS5的X射线粉末衍射在衍射角2θ值为13.6°±0.2°、19.6°±0.2°、21.5°±0.2°、4.7°±0.2°、20.2°±0.2°、22.7°±0.2°、8.4°±0.2°、10.6°±0.2°、24.6°±0.2°、16.1°±0.2°、23.5°±0.2°、26.2°±0.2°、27.5°±0.2°中的任意3处、或4处、或5处、或6处、或7处、或8处、或9处、或10处、或11处、或12处、或13处有特征峰。
非限制性的，在本发明的另一个具体实施方案中，晶型CS5的X射线粉末衍射谱图如附图1所示。
根据本发明的目的，本发明还提供晶型CS5的制备方法，其特征在于，所述方法包括：将化合物(I)原料溶解在醇类溶剂体系中，搅拌析晶后，分离、干燥而获得。
进一步地，所述醇类溶剂优选为甲醇、或乙醇、或丙醇、或它们的任意混合，所述析晶时间优选为1-15天；
更进一步地，所述醇类溶剂优选为甲醇和乙醇的混合溶剂，所述析晶时间优选为5天；
更进一步地，所述甲醇和乙醇的体积比(v:v)优选为1:3-3:1，更优选为1:1。
本发明提供的晶型CS5具有以下有益效果：
1)本发明提供的晶型CS5在模拟生物介质和纯水中具有较高的溶解度，为制剂中晶型的良好溶出提供保障，有利于制剂中活性成分在人体内的有效吸收，达到理想的药物生物利用度和药效。
2)本发明的晶型CS5具有均一的粒径分布。其均匀的粒径有助于简化制剂过程的后处理工艺，如可减少对晶体的研磨，节约成本，也减小研磨中晶型结晶度变化和转晶的风险，提高质量控制。
根据本发明的目的，本发明还提供化合物(I)的晶型CS6(以下称作“晶型CS6”)。
一方面，使用Cu-Kα辐射，所述晶型CS6的X射线粉末衍射在衍射角2θ值为10.1°±0.2°、15.5°±0.2°、20.1°±0.2°处有特征峰。
进一步地，所述晶型CS6的X射线粉末衍射在衍射角2θ值为12.2°±0.2°、27.3°±0.2°、30.3°±0.2°中的1处、或2处、或3处有特征峰。优选的，所述晶型CS6的X射线粉末衍射 在衍射角2θ值为12.2°±0.2°、27.3°±0.2°、30.3°±0.2°处均有特征峰。
另一方面，所述晶型CS6的X射线粉末衍射在衍射角2θ值为10.1°±0.2°、15.5°±0.2°、20.1°±0.2°、12.2°±0.2°、27.3°±0.2°、30.3°±0.2°中的任意3处、或4处、或5处、或6处有特征峰。
非限制性地，在本发明的一个具体实施方案中，晶型CS6的X射线粉末衍射谱图如附图5所示。
根据本发明的目的，本发明还提晶型CS6的制备方法，其特征在于，所述方法包括：将化合物(I)原料溶于酮类和醇类溶剂的混合体系中，并加入高聚物，后挥发得到。
进一步地，所述酮类溶剂优选为丙酮、或甲基乙基酮、或它们的混合，所述醇类溶剂优选为甲醇、或乙醇、或异丙醇、或它们的任意混合，所述酮类溶剂与醇类溶剂的体积比(v:v)优选为1:15-15:1，所述析晶时间优选为1-15天，所述高聚物由等质量的聚己内酯，聚氧乙烯，聚甲基丙烯酸甲酯，羟乙基纤维素和海藻酸钠组成；
更进一步地，所述酮类溶剂优选为丙酮，所述醇类溶剂优选为乙醇，所述酮类溶剂与醇类溶剂的体积比(v:v)优选为1:3，所述析晶时间优选为5天。
本发明提供的晶型CS6具有以下有益效果：
1)本发明提供的晶型CS6具有良好的稳定性。
本发明提供的晶型原料药具有良好的物理、化学稳定。晶型CS6在25℃/60％相对湿度下至少放置3个月晶型未发生变化，其化学纯度在99％以上，且在放置过程中化学纯度基本保持不变。
本发明提供的晶型在制剂中具有良好的物理、化学稳定性。本发明的晶型CS6与辅料混合做成药物制剂后，在25℃/60％相对湿度和40℃/75％相对湿度下至少放置3个月，制剂中本发明的晶型保持不变。
晶型原料药和制剂具有良好的物理、化学稳定性，在存储和制剂工艺过程中，晶型CS6不会转变成其它晶型，且在储存过程中，晶型CS6的化学纯度基本保持不变，从而保证原料药和制剂的质量一致可控。
2)本发明提供的晶型CS6具有低的引湿性，在80％相对湿度下平衡后增重约1.17％，属于略有引湿性。
引湿性会影响药物的稳定性、加工时的流动性和均匀性等，最终影响药物制剂的质量。引湿性还会影响药物的制备、储存与后处理工艺。低引湿性晶型对储存条件要求不苛刻，降低了物料储存以及质量控制成本，具有很强的经济价值。
3)本发明提供的晶型CS6在模拟生物介质和纯水中具有良好的溶解度，为制剂中晶型的良好溶出提供保障，有利于制剂中活性成分在人体内的有效吸收，达到理想的药物生物利用度和药效。
4)本发明晶型CS6还具有良好的溶出度和溶出速率。本发明晶型CS6为活性成分的片剂，在pH＝6.8磷酸盐缓冲溶液介质中，60分钟时的溶出度达到89.6％，有利于其在体内的良好吸收，达到理想的生物利用度。
溶出是吸收的前提条件，良好的体外溶出度使得药物的吸收程度较高，在体内暴露特性更好，从而提高生物利用度，提高药物的疗效；良好的体外溶出速率使得药物在给药后药物在血浆中能够很快达到最高浓度值，进而确保药物快速起效。
根据本发明的目的，本发明还提供一种药物组合物，所述药物组合物包含有效治疗量的本发明的晶型CS5、CS6或它们的任意混合，以及至少一种药学上可接受的载体、稀释剂或赋形剂。
进一步地，本发明提供的晶型CS5、CS6或它们的任意混合在制备前列腺素D2受体2拮抗剂药物制剂中的用途。
更进一步地，本发明提供的晶型CS5和CS6或它们的任意混合在制备治疗治疗哮喘和/或过敏性皮炎和/或过敏性鼻炎药物制剂中的用途。
根据本发明，作为原料的所述化合物(I)指其固体(晶型或无定形)、半固体、蜡或油形式。优选地，作为原料的所述式(I)化合物为固体粉末形式。
本发明中，“晶体”或“多晶型”指的是被所示的X射线衍射图表征所证实的。本领域技术人员能够理解，这里所讨论的理化性质可以被表征，其中的实验误差取决于仪器的条件、样品的准备和样品的纯度。特别是，本领域技术人员公知，X射线衍射图通常会随着仪器的条件而有所改变。特别需要指出的是，X射线衍射图的相对强度也可能随着实验条件的变化而变化，所以峰强度的顺序不能作为唯一或决定性因素。事实上，XRPD图谱中衍射峰的相对强度与晶体的择优取向有关，本文所示的峰强度为说明性而非用于绝对比较。另外，峰角度的实验误差通常在5％或更少，这些角度的误差也应该被考虑进去，通常允许有±0.2°的误差。另外，由于样品高度等实验因素的影响，会造成峰角度的整体偏移，通常允许一定的偏移。因而，本领域技术人员可以理解的是，本发明中一个晶型的X射线衍射图不必和这里所指的例子中的X射线衍射图完全一致，本文所述“XRPD图相同”并非指绝对相同，相同峰位置可相差±0.2°且峰强度允许一定可变性。任何具有和这些图谱中的特征峰相同或相似的图的晶型均属于本发明的范畴之内。本领域技术人员能够将本发明所列的图谱和一个未知晶型的图谱相比较，以证实这两组图谱反映的是相同还是不同的晶型。
在一些实施方案中，本发明的晶型CS5和CS6是纯的、单一的，基本没有混合任何其他晶型。本发明中，“基本没有”当用来指新晶型时指这个晶型含有少于20％(重量)的其他晶型，尤其指少于10％(重量)的其他晶型，更指少于5％(重量)的其他晶型，更指少于1％(重量)的其他晶型。
需要说明的是，本发明中提及的数值及数值范围不应被狭隘地理解为数值或数值范围本身，本领域技术人员应当理解其可以根据具体技术环境的不同，在不背离本发明精神和原则的基础上围绕具体数值有所浮动，本发明中，这种本领域技术人员可预见的浮动范围多以术语“约”来表示。
附图说明
图1为根据本发明实施例1所得晶型CS5的XRPD图。
图2为根据本发明实施例1所得晶型CS5的DSC图。
图3为根据本发明实施例1所得晶型CS5的TGA图。
图4为根据本发明实施例2所得晶型CS5的XRPD图。
图5为本发明晶型CS5的PSD图。
图6为根据本发明实施例3所得晶型CS6的XRPD图。
图7为根据本发明实施例3所得晶型CS6的 1HNMR图。
图8为根据本发明实施例3所得晶型CS6的DSC图。
图9为根据本发明实施例3所得晶型CS6的TGA图。
图10为本发明晶型CS6的DVS图。
图11为本发明晶型CS6在25℃/60％相对湿度条件下放置6个月前后的XRPD图(上图为放置前，下图为放置后)。
图12为本发明晶型CS6片剂的体外溶出曲线。
具体实施方式
本发明进一步参考以下实施例限定，所述实施例详细描述本发明的晶型的制备和使用方法。
本发明中所用到的缩写的解释如下：
XRPD：X射线粉末衍射
DSC：差示扫描量热分析
TGA：热重分析
DVS：动态水分吸附
HPLC：高效液相色谱
1HNMR：核磁共振氢谱
PSD：粒径分布
采集数据所用的仪器及方法：
本发明所述的X射线粉末衍射图在Panalytical Empyrean X射线粉末衍射仪上采集。本发明所述的X射线粉末衍射的方法参数如下：
X射线反射参数：Cu,Kα
Kα1
Figure PCTCN2018095694-appb-000002
：1.540598；Kα2
Figure PCTCN2018095694-appb-000003
：1.544426
Kα2/Kα1强度比例：0.50
电压：45仟伏特(kV)
电流：40毫安培(mA)
扫描范围：自3.0至40.0度
本发明所述的差示扫描量热分析(DSC)图在TA Q2000上采集。本发明所述的差示扫描量热分析(DSC)的方法参数如下：
扫描速率：如无特别说明为10℃/min
保护气体：N 2
本发明所述的热重分析(TGA)图在TA Q500上采集。本发明所述的热重分析(TGA)的方法参数如下：
扫描速率：10℃/min
保护气体：N 2
本发明所述动态水分吸附(DVS)图在由SMS公司(Surface Measurement Systems Ltd.)生产的Intrinsic动态水分吸附仪上采集。所述的动态水分吸附仪的方法参数如下：
温度：25℃
载气，流速：N 2,200毫升/分钟
单位时间质量变化：0.002％/分钟
相对湿度范围：0％RH-95％RH
测试晶型化学纯度的HPLC仪器参数：
高效液相色谱(HPLC)数据采集来自于安捷伦1260，所用检测器为紫外可变波长检测器(VWD)。本发明所述的HPLC方法参数如下：
色谱柱：Xbridge C8,150×4.6mm,3.5μm
流动相：A:0.1％TFA in H 2O
B:0.1％TFA in acetonitrile
洗脱梯度：
Time(min) ％B
0.0 15
20.0 80
25.0 80
26.0 15
32.0 15
流速：1.0mL/min
进样量：5μL
柱温：40℃
稀释剂：ACN:H 2O＝1:1
测试溶解度的HPLC仪器参数：
高效液相色谱(HPLC)数据采集来自于安捷伦1260，所用检测器为紫外可变波长检测器(VWD)。本发明所述的HPLC方法参数如下：
色谱柱：Xbridge C18,150×4.6mm,5μm
流动相：A:0.1％TFA in H 2O
B:0.1％TFA in acetonitrile
洗脱梯度：
Time(min) ％B
0.0 40
8.0 40
流速：1.0mL/min
进样量：5μL
柱温：40℃
稀释剂：ACN:H 2O＝1:1
本发明中所述的粒径分布结果是在Microtrac公司的S3500型激光粒度分析仪上采集。Microtrac S3500配备SDC(Sample Delivery Controller)进样系统。本测试采用湿法，测试 分散介质为Isopar G。所述的激光粒度分析仪的方法参数如下：
Figure PCTCN2018095694-appb-000004
*：流速60％为65毫升/秒的60％。
核磁共振氢谱数据( 1HNMR)采自于Bruker Avance II DMX 400M HZ核磁共振波谱仪。称量1-5mg样品，用0.5mL氘代二甲亚砜溶解，配成2-10mg/mL的溶液。
除非特殊说明，以下实施例均在室温条件下操作。所述“室温”不是精确的温度值，是指10-30℃温度范围。
以下实施例中所使用到的QAW-039是根据现有技术制备得到，例如根据WO2005123731A1中公开的制备方法得到。
实施例1：晶型CS5的制备方法
将108.1mg的化合物(I)加至2.0mL体积比为1:1的甲醇和乙醇的混合溶剂中，室温下搅拌5天，分离所得固体并真空干燥得到本发明的晶型CS5。其XRPD数据如图1、表1所示。
本实施例所得晶型CS5的DSC如图2所示，加热至95℃附近开始出现一个吸热峰，该吸热峰为晶型CS5的脱水吸热峰。
本实施例所得晶型CS5的TGA如附图3所示，加热至140℃附近时具有约10.2％的失重。
表1
衍射角2θ d值 强度％
4.74 18.63 48.83
8.37 10.56 41.65
10.59 8.35 22.19
12.65 7.00 9.64
12.92 6.85 20.64
13.60 6.51 90.28
14.71 6.02 6.36
16.09 5.51 21.23
17.73 5.00 8.30
19.58 4.53 63.93
20.16 4.40 73.91
21.50 4.13 100.00
21.95 4.05 14.18
22.67 3.92 26.01
23.53 3.78 22.98
24.17 3.68 19.70
24.58 3.62 27.23
26.19 3.40 24.95
27.52 3.24 24.18
27.99 3.19 25.82
29.82 3.00 10.38
31.83 2.81 14.89
32.76 2.73 4.55
34.07 2.63 3.37
36.37 2.47 5.86
实施例2：晶型CS5的制备方法
将39.4mg的化合物(I)加至0.4mL体积比为1:1的甲醇和乙醇的混合溶剂中，5℃下搅拌16小时，分离所得固体并干燥得到本发明的晶型CS5。其XRPD数据如图4、表2所示。
表2
衍射角2θ d值 强度％
4.76 18.57 33.01
8.38 10.55 36.29
10.60 8.35 20.10
12.68 6.98 11.37
12.91 6.86 21.07
13.61 6.51 87.99
14.69 6.03 5.71
16.08 5.51 20.59
17.70 5.01 6.87
19.54 4.54 46.22
19.72 4.50 25.61
20.16 4.40 55.81
21.50 4.13 100.00
21.92 4.05 12.57
22.62 3.93 19.56
23.17 3.84 6.24
23.57 3.78 20.46
24.23 3.67 12.58
24.61 3.62 27.92
25.74 3.46 6.54
26.21 3.40 21.82
27.51 3.24 16.35
27.95 3.19 16.13
29.84 2.99 8.80
31.81 2.81 8.50
32.69 2.74 4.07
34.03 2.63 2.15
36.34 2.47 4.18
39.17 2.30 2.40
实施例3：晶型CS5的动态溶解度
胃肠道液体例如SGF(模拟胃液)、FaSSIF(模拟禁食状态肠液)、FeSSIF(模拟喂食状态肠液)属于生物相关介质，此类介质能更好地反映胃肠道生理环境对药物释放产生的影响，在此类介质中测试的溶解度与人体环境中的溶解度更加接近。
取本发明的晶型CS5，分别溶于SGF、FaSSIF、FeSSIF和水配制成的饱和溶液，平衡1小时后用高效液相色谱(HPLC)测试饱和溶液中样品的含量(微克/毫升)。晶型CS5的溶解度实验结果如表3所示。
表3晶型CS5在SGF、FeSSIF、FaSSIF和水中的溶解度
Figure PCTCN2018095694-appb-000005
结果表明，本发明晶型CS5在SGF，FeSSIF，FaSSIF和纯水中具有较高的溶解度。
实施例4：晶型CS5的PSD
取10-30mg本发明的晶型CS5，然后加入10mL Isopar G(含有0.2％卵磷脂)，将待测样品充分混合均匀后加入SDC进样系统中，使样品量指示图达到合适位置，开始实验，进行粒径分布的测试，从而得到按照体积计算的平均粒径、粒径分布中(体积分布)占10％所对应的粒径、粒径分布中(体积分布)占50％所对应的粒径。粒径分布中(体积分布)占90％所对应的粒径以及晶型粒度分布图。
结果如表4所示，PSD图如图5所示。结果表明，晶型CS5具有均一的粒径分布。
表4晶型CS5的PSD数据
晶型 MV/μm D(10)/μm D(50)/μm D(90)/μm
CS5 17.04 5.48 12.14 27.19
注：
MV：按照体积计算的平均粒径
D10：表示粒径分布中(体积分布)占10％所对应的粒径
D50：表示粒径分布中(体积分布)占50％所对应的粒径，又称中位径
D90：表示粒径分布中(体积分布)占90％所对应的粒径
实施例5：晶型CS6的制备方法
将约9.0mg的化合物(I)溶解于0.6mL体积比为1:3的丙酮和乙醇的混合溶剂中，过滤后加入等质量的由聚己内酯、聚氧乙烯、聚甲基丙烯酸甲酯、羟乙基纤维素和海藻酸钠组成的高聚物，于室温下挥发约5天析出固体。经检测，所得固体为晶型CS6。其XRPD数据如图6、表5所示。
核磁共振氢谱谱图如图7所示，核磁数据为： 1H NMR(400MHz,DMSO)δ8.26(s,1H),8.13(d,J＝4.7Hz,1H),8.04(d,J＝7.9Hz,1H),7.95(d,J＝7.7Hz,1H),7.11(dd,J＝7.8,4.7Hz,1H),6.49(d,J＝8.2Hz,1H),5.76(s,2H),3.72(s,2H),3.28(s,3H),2.28(s,3H)。
本实施例所得晶型CS6的DSC如图8所示，加热至46℃附近开始出现一个吸热峰，该吸热峰为晶型CS6的脱水吸热峰。
本实施例所得晶型CS6的TGA如图9所示，加热至140℃附近时具有约5.5％的失重。
表5
衍射角2θ d值 强度％
6.18 14.30 0.79
10.08 8.78 53.86
12.24 7.23 4.12
15.47 5.73 50.31
18.38 4.83 1.41
20.10 4.42 100.00
20.95 4.24 1.49
21.40 4.15 0.87
22.13 4.02 0.92
22.69 3.92 0.96
25.48 3.50 0.42
26.20 3.40 0.53
27.29 3.27 3.92
28.84 3.10 0.51
30.25 2.95 2.87
32.20 2.78 0.39
33.45 2.68 0.76
35.65 2.52 1.06
37.02 2.43 0.67
实施例6：晶型CS6的引湿性
称取本发明晶型CS6约10mg进行动态水分吸附(DVS)测试其引湿性，结果如表6所示，80％相对湿度下晶型CS6增重量仅为1.17％，属于略有引湿性，DVS图如图10所示。
表6
晶型 80％相对湿度下增重量 引湿性
CS6 1.17％ 略有引湿性
结果表明，本发明晶型CS6具有低的引湿性。
关于引湿性特征描述与引湿性增重的界定(中国药典2015年版通则9103药物引湿性试验指导原则，实验条件：25℃±1℃，相对湿度为80％±2％)：
潮解：吸收足量水分形成液体
极具引湿性：引湿增重不小于15.0％
有引湿性：引湿增重小于15.0％但不小于2.0％
略有引湿性：引湿增重小于2.0％但不小于0.2％
无或几乎无引湿性：引湿增重小于0.2％
实施例7：晶型CS6的稳定性
取本发明晶型CS6的样品置于25℃/60％相对湿度下敞口放置，测试放置前后的晶型和 化学纯度的变化，结果如表7所示：
表7
Figure PCTCN2018095694-appb-000006
本发明晶型CS6在25℃/60％相对湿度条件下，放置3个月前后晶型未发生改变且化学纯度基本保持不变，说明本发明晶型CS2具有良好的物理、化学稳定性。
实施例8：晶型CS6的动态溶解度
胃肠道液体例如SGF(模拟胃液)、FaSSIF(模拟禁食状态肠液)、FeSSIF(模拟喂食状态肠液)属于生物相关介质，此类介质能更好地反映胃肠道生理环境对药物释放产生的影响，在此类介质中测试的溶解度与人体环境中的溶解度更加接近。
取本发明的晶型CS6，分别溶于SGF、FaSSIF、FeSSIF和水配制成的饱和溶液，平衡1小时后用高效液相色谱(HPLC)测试饱和溶液中样品的含量(微克/毫升)。晶型CS5的溶解度实验结果如表8所示。
表8晶型CS6在SGF、FeSSIF、FaSSIF和水中的溶解度
Figure PCTCN2018095694-appb-000007
结果表明，本发明晶型CS6的在SGF，FeSSIF，FaSSIF和纯水中具有良好的溶解度，为制剂中晶型的良好溶出提供保障，有利于制剂中活性成分在人体内的有效吸收，达到理想的药物生物利用度和药效。
实施例9：晶型CS6的制剂
1.化合物(I)片剂的制备：
称取化合物(I)的晶型CS6、微晶纤维素、交联羧甲基纤维素钠和硬脂酸镁(各组分含量如下表9所示)，混合2分钟。用手动压片机压制成片，直径6mm圆形冲模，压力5KN±1KN，片重75mg±1mg。用35cc HDPE瓶包装(每瓶一片)，每瓶含有1g干燥剂，用封口机封口。经检测，制剂制备前后，活性成分的晶型未发生变化。
表9
片剂成分 质量(mg/片) 质量比(％)
晶型CS6 15 20
微晶纤维素 55.5 74
交联羧甲基纤维素钠 3.75 5
硬脂酸镁 0.75 1
合计 75 100
2.晶型CS6在制剂中的稳定性：
取上述制备的片剂在25℃/60％相对湿度和40℃/75％相对湿度条件下放置3个月，经检测，在含晶型CS6的片剂中，晶型未发生变化。结果如下表10所示，说明晶型CS6在制剂中具有很好的稳定性。
表10晶型CS6在制剂中的稳定性
Figure PCTCN2018095694-appb-000008
实施例10：晶型CS6的体外溶出度与体外溶出速率
对实施例9获得的含晶型CS6的片剂测试体外溶出情况，溶出度的测定按照中国药典2015年版0931溶出度与释放度测定法，条件如下：
溶出介质：pH＝6.8磷酸盐缓冲溶液
溶出方法：桨法
介质体积：900mL
转速：75rpm
介质温度：37℃
晶型CS6的体外溶出情况如下表11，图12所示，表明以本发明晶型为活性成分的片剂具有良好的溶出度和溶出速率。
表11
Figure PCTCN2018095694-appb-000009
Figure PCTCN2018095694-appb-000010
上述实施例只为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰，都应涵盖在本发明的保护范围之内。

Claims (15)

  1. 一种化合物(I)的晶型CS6，其特征在于，其X射线粉末衍射在衍射角2θ值为10.1°±0.2°、15.5°±0.2°、20.1°±0.2°、12.2°±0.2°处有特征峰。
  2. 一种化合物(I)晶型CS6的制备方法，其特征在于，所述方法为：将化合物(I)溶于酮类和醇类溶剂的混合体系中，并加入高聚物，后挥发得到。
  3. 根据权利要求2所述的制备方法，所述酮类溶剂为丙酮、或甲基乙基酮、或它们的任意混合，所述醇类溶剂为甲醇、或乙醇、或异丙醇、或它们的任意混合，所述酮类溶剂与醇类溶剂的体积比(v:v)为1:15-15:1，所述析晶时间为1-15天，所述高聚物由等质量的聚己内酯，聚氧乙烯，聚甲基丙烯酸甲酯，羟乙基纤维素和海藻酸钠组成。
  4. 根据权利要求3所述的制备方法，所述酮类溶剂为丙酮，所述醇类溶剂为乙醇，所述酮类溶剂与醇类溶剂的体积比(v:v)为1:3，所述析晶时间为5天。
  5. 一种化合物(I)的晶型CS5，其特征在于，其X射线粉末衍射在衍射角2θ值为13.6°±0.2°、19.6°±0.2°、21.5°±0.2°处有特征峰。
  6. 根据权利要求5所述的晶型CS5，其特征还在于，其X射线粉末衍射在衍射角2θ值为4.7°±0.2°、20.2°±0.2°、22.7°±0.2°中的一处或多处有特征峰。
  7. 根据权利要求5所述的晶型CS5，其特征还在于，其X射线粉末衍射在衍射角2θ值为8.4°±0.2°、10.6°±0.2°、24.6°±0.2°中的一处或多处有特征峰。
  8. 一种化合物(I)晶型CS5的制备方法，其特征在于，所述方法为：将化合物(I)溶解在醇类溶剂体系中，搅拌析晶后，分离、干燥而获得。
  9. 根据权利要求8所述的制备方法，所述醇类溶剂为甲醇、或乙醇、或丙醇或它们的任意混合，所述析晶时间为1-15天。
  10. 根据权利要求9所述的制备方法，所述醇类溶剂为甲醇和乙醇的混合溶剂，所述析晶时间为5天。
  11. 根据权利要求10所述的制备方法，所述甲醇和乙醇的体积比(v:v)为1:3-3:1。
  12. 根据权利要求11所述的制备方法，所述甲醇和乙醇的体积比(v:v)为1:1。
  13. 一种药物组合物，所述药物组合物包含有效治疗量的权利要求1中所述的晶型CS6、权利要求5中所述的晶型CS5或它们的任意混合及药学上可接受的载体、稀释剂或赋形剂。
  14. 权利要求1中所述的晶型CS6、权利要求5中所述的晶型CS5或它们的任意混合在生产用于制备前列腺素D2受体2拮抗剂药物制剂中的用途。
  15. 权利要求1中所述的晶型CS6、权利要求5中所述的晶型CS5或它们的任意混合在生产 用于制备治疗哮喘和/或过敏性皮炎和/或过敏性鼻炎药物制剂中的用途。
PCT/CN2018/095694 2017-07-14 2018-07-13 Qaw-039的晶型及其制备方法和用途 Ceased WO2019011337A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710577126 2017-07-14
CN201710577126.9 2017-07-14

Publications (1)

Publication Number Publication Date
WO2019011337A1 true WO2019011337A1 (zh) 2019-01-17

Family

ID=65001049

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2018/095690 Ceased WO2019011336A1 (zh) 2017-07-14 2018-07-13 Qaw-039的晶型及其制备方法和用途
PCT/CN2018/095694 Ceased WO2019011337A1 (zh) 2017-07-14 2018-07-13 Qaw-039的晶型及其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/095690 Ceased WO2019011336A1 (zh) 2017-07-14 2018-07-13 Qaw-039的晶型及其制备方法和用途

Country Status (1)

Country Link
WO (2) WO2019011336A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210610A1 (en) * 2004-06-17 2010-08-19 Kamlesh Jagdis Bala Organic compounds
CN106188040A (zh) * 2016-06-28 2016-12-07 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法
WO2017056001A1 (en) * 2015-09-29 2017-04-06 Novartis Ag Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1h-pyrrolo [2,3-b]pyridin-3-yl-acetic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210610A1 (en) * 2004-06-17 2010-08-19 Kamlesh Jagdis Bala Organic compounds
WO2017056001A1 (en) * 2015-09-29 2017-04-06 Novartis Ag Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1h-pyrrolo [2,3-b]pyridin-3-yl-acetic acid
CN106188040A (zh) * 2016-06-28 2016-12-07 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANDHAM, D.A. ET AL.: "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma", ACS MEDICINAL CHEMISTRY LETTERS, vol. 8, 25 April 2017 (2017-04-25), pages 582 - 586, XP002781657 *

Also Published As

Publication number Publication date
WO2019011336A1 (zh) 2019-01-17

Similar Documents

Publication Publication Date Title
WO2019052133A1 (zh) Gsk1278863的晶型及其制备方法和制药用途
WO2021244323A1 (zh) 一种乌帕替尼的晶型及其制备方法和用途
JP2010535176A (ja) ジヒドロプテリジノン誘導体の結晶形
CN110799501B (zh) 一种食欲素受体拮抗剂的晶型及其制备方法和用途
WO2018108101A1 (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
CN111094290B (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
CN109195980B (zh) 一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途
WO2016141891A1 (zh) Jak抑制剂的晶型及其制备方法
EP3553058A1 (en) Crystal form of bromodomain protein inhibitor drug, preparation method and use thereof
EP4180435A1 (en) Crystal form of upadacitinib, preparation method therefor, and use thereof
WO2018006870A1 (zh) Galunisertib的晶型及其制备方法和用途
WO2018036558A1 (zh) 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途
WO2019042219A1 (zh) 奥扎莫德盐酸盐的晶型及其制备方法
WO2018233437A1 (zh) 巴瑞克替尼的晶型及其制备方法
EP3572399A1 (en) Crystal form of gft-505 and preparation method and use thereof
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
WO2019134455A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
WO2019011337A1 (zh) Qaw-039的晶型及其制备方法和用途
US10266523B2 (en) Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
JP2019089822A (ja) トピロキソスタットの新規結晶形及びその製造方法
WO2023165501A1 (zh) Azd5305的晶型及其制备方法和用途
CN116802183A (zh) 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
EP4509499A1 (en) Polymorph of 7,8-dihydroxyflavone, and preparation method therefor
WO2018077187A1 (zh) Ap26113的新晶型及其制备方法
WO2018157741A1 (zh) Sb-939的盐的晶型及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18831062

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18831062

Country of ref document: EP

Kind code of ref document: A1